4-Nitrocyclohexanol | 121936-53-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Nitrocyclohexanol
• 英文别名: 4-nitrocyclohexan-1-ol
• CAS: 121936-53-6
• 化学式: C₆H₁₁NO₃
• 分子量: 145.158
• InChiKey: ZJTAOPVJQSDQTJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Nitrocyclohexanol 在 palladium 10% on activated carbon 、 氢气 、 caesium carbonate 、 N,N'-二环己基碳二亚胺 作用下， 以 四氢呋喃 、 乙酸乙酯 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 7.5h， 生成
  参考文献：
  名称：

  Discovery and In Vitro Characterization of BAY 2686013, an Allosteric Small Molecule Antagonist of the Human Pituitary Adenylate Cyclase-Activating Polypeptide Receptor

  摘要：

  DOI：

  10.1124/molpharm.122.000662
• 作为产物：
  描述：

  (1,1-dimethylethyl)dimethyl<(4-nitrocyclohexyl)oxy>silane 、 四丁基氟化铵 以74%的产率得到
  参考文献：
  名称：

  JANDA, KIM D.;ASHLEY, JON A., SYNTH. COMMUN., 20,(1990) N, C. 1073-1082

  摘要：

  DOI：

文献信息

• FUSED HETEROCYCLIC COMPOUND AND APPLICATION THEREOF
  申请人：Matsunaga Nobuyuki

  公开号：US20130131050A1

  公开（公告）日：2013-05-23

  The present invention provides a compound useful for the prophylaxis or treatment of eicosanoid-associated diseases such as atherosclerosis, atherothrombosis, diabetes, obesity, asthma, fever, pain, cancer, rheumatism, osteoarthritis, atopic dermatitis and the like, and having superior pharmacological action, physicochemical properties and the like. The present invention relates to a compound represented by the following formula: wherein each symbol is as defined in the specification, or a salt thereof.

  本发明提供了一种化合物，用于预防或治疗与前列腺素相关的疾病，如动脉粥样硬化、动脉血栓形成、糖尿病、肥胖、哮喘、发热、疼痛、癌症、风湿病、骨关节炎、特应性皮炎等，并具有优越的药理作用、理化性质等。本发明涉及一种由以下式表示的化合物：其中每个符号如规范中定义的那样，或其盐。
• [EN] NOVEL COMPOUNDS WHICH ACTIVATE ESTROGEN RECEPTORS AND COMPOSITIONS AND METHODS OF USING THE SAME<br/>[FR] NOUVEAUX COMPOSÉS QUI ACTIVENT LES RÉCEPTEURS D'ŒSTROGÈNE ET COMPOSITIONS ET PROCÉDÉS D'UTILISATION DE CEUX-CI
  申请人：UNIV ILLINOIS

  公开号：WO2017120507A1

  公开（公告）日：2017-07-13

  Provided are compounds of formulae provided herein. The compounds may include pathway-preferential estrogens (PaPEs) derivatives with tissue-selective activities. Also provided are pharmaceutical compositions comprising the compounds, as well as methods of treating a disease or condition including administering the compounds. The disease or condition may include postmenopausal symptoms, cardiovascular disease, stroke, vascular disease, bone disease, metabolic disease, arthritis, osteoporosis, obesity, vasomotor/hot flush, cognitive decline, cancer including breast cancer.

  提供了本处所提供的化合物的化学式。这些化合物可能包括具有组织选择性活性的途径优先雌激素（PaPEs）衍生物。此外，还提供了包含这些化合物的药物组合物，以及治疗疾病或症状的方法，包括给予这些化合物。这种疾病或症状可能包括绝经后症状、心血管疾病、中风、血管疾病、骨疾病、代谢疾病、关节炎、骨质疏松症、肥胖、血管运动/潮热、认知能力下降、癌症包括乳腺癌。
• Epi-epibatidine derivatives, a process and intermediates for preparing them and epi-epibatidine and medicaments containing the epi-epibatidine derivatives and/or epi-epibatidine and the use of them
  申请人：EGIS GYOGYSZERGYAR

  公开号：EP0657455A1

  公开（公告）日：1995-06-14

  The subject-matter of the invention are epi-epibatidine derivatives of general formula    wherein Rstands for a C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkinyl, C₃₋₇-cycloalkyl, aryl, heteroaryl, aryl-C₁₋₄-alkyl or heteroaryl-C₁₋₄-alkyl group, said groups optionally being substituted by 1 or more C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkinyl, C₃₋₇-cycloalkyl, aryl, heteroaryl, aryl-C₁₋₄-alkyl, heteroaryl-C₁₋₄-alkyl, hydroxy, C₁₋₄-alkoxy, phenoxy, halogen, halogeno-C₁₋₄-alkyl and/or amino, amido and/or sulfonamido substituent(s), optionally mono- or di-C₁₋₄-alkyl-, -C₂₋₄-alkenyl- and/or -C₂₋₄-alkinyl substituted, and R'represents hydrogen or a C₁₋₄-alkyl, C₂₋₄-alkenyl, C₂₋₄-alkinyl, C₃₋₇-cycloalkyl, C₃₋₇-cycloalkenyl, C₃₋₇-cycloalkinyl, aryl-C₁₋₄-alkyl, aryl, hetero-aryl, halogeno-C₁₋₄-alkyl, hydroxy-C₁₋₄-alkyl or, preferably C₁₋₄-aliphatic; aromatic or heterocyclic, acyl group    with the proviso that, if R'stands for hydrogen, Ris different from 6-(chloro)-pyrid-3-yl as well as optically active forms and acid addition salts thereof. Further aspects of the invention are concerned with a process and intermediates for preparing these compounds as well as medicaments containing them and their use.

  本发明的主题是一般式为的外显子-外显子巴替啡衍生物，其中R代表C₁₋₄-烷基，C₂₋₄-烯基，C₂₋₄-炔基，C₃₋₇-环烷基，芳基，杂芳基，芳基-C₁₋₄-烷基或杂芳基-C₁₋₄-烷基基团，该基团可以被1个或多个C₁₋₄-烷基，C₂₋₄-烯基，C₂₋₄-炔基，C₃₋₇-环烷基，芳基，杂芳基，芳基-C₁₋₄-烷基，杂芳基-C₁₋₄-烷基，羟基，C₁₋₄-烷氧基，苯氧基，卤素，卤代-C₁₋₄-烷基和/或氨基，酰胺基和/或磺酰胺基取代，可选地为单烷基或双烷基，-C₂₋₄-烯基-和/或-C₂₋₄-炔基取代，并且R'表示氢或C₁₋₄-烷基，C₂₋₄-烯基，C₂₋₄-炔基，C₃₋₇-环烷基，C₃₋₇-环烯基，C₃₋₇-环炔基，芳基-C₁₋₄-烷基，芳基，杂芳基，卤代-C₁₋₄-烷基，羟基-C₁₋₄-烷基或优选的C₁₋₄-脂肪族；芳香族或杂环族，酰基基团，但是，如果R'代表氢，则R与6-(氯)-吡啶-3-基不同，以及它们的光学活性形式和酸加成盐。本发明的其他方面涉及制备这些化合物的过程和中间体，以及含有它们的药物和它们的用途。
• ABSORBABLE POLYURETHANES AND METHODS OF USE THEREOF
  申请人：BEZWADA BIOMEDICAL, LLC

  公开号：US20150080301A1

  公开（公告）日：2015-03-19

  Disclosed are novel bioabsorbable and biodegradable monomer compounds, bioabsorbable and biodegradable polymers therefrom, and methods of making such monomers and polymers, which are useful in pharmaceutical delivery systems, tissue engineering applications, tissue adhesives products, implantable medical devices, foams and reticulated foams for wound healing and drug delivery, bone hemostats and bone void fillers, adhesion prevention barriers, meshes, filters, stents, medical device coatings, pharmaceutical drug formulations, consumer product and cosmetic and pharmaceutical packaging, apparel, infusion devices, blood collection tubes and devices, other medical tubes, skin care products, and transdermal drug delivery materials.

  本发明公开了一种新型的可生物吸收和可生物降解的单体化合物，以及由此制得的可生物吸收和可生物降解的聚合物，以及制备这些单体和聚合物的方法。这些单体和聚合物可用于制造药物输送系统、组织工程应用、组织粘合产品、可植入医疗器械、用于伤口愈合和药物输送的泡沫和网状泡沫、骨止血剂和骨空隙填充剂、粘附预防屏障、网格、过滤器、支架、医疗器械涂层、制药药物配方、消费品、化妆品和制药包装、服装、输液器、采血管和设备、其他医疗管道、皮肤护理产品和经皮药物输送材料。
• CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH
  申请人：GILEAD SCIENCES, INC.

  公开号：EP1509537B9

  公开（公告）日：2007-11-14